Skip to content

Omaroon

Quantitative Phe monitoring, closer to the clinical decision.

Omaroon is developing a quantitative phenylalanine monitoring system for PKU, combining a single-use test, compact reader, and connected workflow.

Explore the technologyContact us
Concept motif of the Omaroon platformAn abstract single-use test inserted into a compact reader, linked to a connected workflow panel. Illustrative only; not a product design.Single-use testCompact readerConnected workflow

Concept illustration only. Not a product design.

Where we are

Today, and where we are headed.

Omaroon's quantitative Phe monitoring system is investigational. Current work is professional-use evaluation; connected home monitoring is a planned future direction.

  1. Step 1 · Current development

    Today

    Professional-use / prepared-plasma evaluation

    Development is focused on professional-use evaluation using prepared plasma. The system is investigational and is not available for commercial clinical use.

  2. Step 2 · Future direction

    Planned

    Connected home monitoring

    A planned future extension, subject to additional development, validation, and applicable regulatory authorization. It is not something the current system does.

Why it matters

PKU care depends on knowing Phe levels.

Phenylketonuria (PKU) is an inherited condition in which the body cannot break down the amino acid phenylalanine (Phe). Without treatment, Phe builds up in the blood and can harm the brain.

People with PKU follow a carefully managed diet for life, guided by regular blood Phe measurements reviewed with their metabolic clinic.

Learn more about PKU

  • Samples often travel

    Blood Phe is usually measured in a laboratory, and samples may need to be mailed there.

  • Results take time

    Laboratory-based Phe monitoring can take several days, particularly when samples must be mailed to a laboratory.

  • Decisions wait on results

    Care teams use Phe results to guide diet and treatment, so the wait matters.

Technology

One platform, three components.

An investigational quantitative phenylalanine monitoring platform.

  1. COMPONENT 01

    Single-use test

    Designed for quantitative Phe measurement.

  2. COMPONENT 02

    Compact reader

    Designed for near-patient quantitative analysis.

  3. COMPONENT 03

    Connected workflow

    Designed to support longitudinal results and future clinician-connected monitoring.

About the technology

Funding support

Supported by NSF and NIH SBIR awards.

Non-dilutive federal research funding, alongside clinical and research collaborators.

  • NSF SBIR Phase I2021

    U.S. National Science Foundation

    Award 2051803

  • NSF SBIR Phase II2024

    U.S. National Science Foundation

    Award 2332518

  • NIH/NIGMS SBIR Phase I2026

    National Institute of General Medical Sciences, National Institutes of Health

    Award R43GM166946

Omaroon's work has been supported by the U.S. National Science Foundation and by the National Institute of General Medical Sciences of the National Institutes of Health. Content on this site is solely the responsibility of Omaroon and does not necessarily represent the official views of NSF or NIH. Federal funding does not imply endorsement.

We work with clinical and research collaborators. Ways to collaborate

Interested in working with Omaroon?

We welcome inquiries about clinical collaboration, research collaboration, product development and manufacturing, and investment.

Start a conversation